Loading...
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
Shorter door-to-needle times for administering tissue plasminogen activator (tPA) to stroke patients are associated with lower rates of mortality and readmissions at 1 year, according to a JAMA study.
Researchers identified over 55,000 Medicare beneficiaries who were treated with tPA for acute ischemic stroke within 4.5 hours of symptom onset. Patients given tPA within 45 minutes of hospital arrival (so-called door-to-needle time) had lower all-cause mortality (31% vs. 35%) and lower all-cause readmission (38% vs. 41%) at 1 year than those given tPA after 45 minutes. Similar results were seen when a 60-minute cutoff was used.
A commentator concludes: "The findings are yet another reason for clinicians and health systems to design stroke services that can treat patients with acute ischemic stroke with thrombolytic therapy in a rapid fashion."
Comment
LINK(S):
JAMA article (Free abstract)
JAMA editor's note (Free)
Background: NEJM Journal Watch Emergency Medicine coverage of door-to-needle times (Your NEJM Journal Watch registration required)